Advances in pancreas transplantation

George W Burke, Gaetano Ciancio, Hans W. Sollinger

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Despite early obstacles impacting the success of pancreatic transplantation, the introduction of new procedures and new immunosuppressive therapies during the past 2 decades has improved outcomes for pancreatic transplant recipients. For example, the use of bladder drainage and better human leukocyte antigen matching has helped overcome some of the early obstacles of pancreatic transplantation. In addition, the introduction of tacrolimus in 1994 and mycophenolate mofetil in 1996 has helped lower rates of acute rejection and increase graft survival, with less nephrotoxicity than treatment with cyclosporine. Regimens allowing the tapering of corticosteroids have also helped reduce the rates of acute pancreas rejection. To further improve therapeutic options for patients with type 1 diabetes or end-stage renal disease, pancreatic islet transplantation and organ and islet xenotransplantation should be further explored.

Original languageEnglish
JournalTransplantation
Volume77
Issue number9
StatePublished - May 15 2004

Fingerprint

Pancreas Transplantation
Transplantation
Mycophenolic Acid
Islets of Langerhans Transplantation
Heterologous Transplantation
Tacrolimus
Graft Survival
Immunosuppressive Agents
HLA Antigens
Type 1 Diabetes Mellitus
Cyclosporine
Chronic Kidney Failure
Drainage
Pancreas
Adrenal Cortex Hormones
Urinary Bladder
Therapeutics

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

Advances in pancreas transplantation. / Burke, George W; Ciancio, Gaetano; Sollinger, Hans W.

In: Transplantation, Vol. 77, No. 9, 15.05.2004.

Research output: Contribution to journalArticle

@article{bb3eb178691e464cb5c02517ae6ef473,
title = "Advances in pancreas transplantation",
abstract = "Despite early obstacles impacting the success of pancreatic transplantation, the introduction of new procedures and new immunosuppressive therapies during the past 2 decades has improved outcomes for pancreatic transplant recipients. For example, the use of bladder drainage and better human leukocyte antigen matching has helped overcome some of the early obstacles of pancreatic transplantation. In addition, the introduction of tacrolimus in 1994 and mycophenolate mofetil in 1996 has helped lower rates of acute rejection and increase graft survival, with less nephrotoxicity than treatment with cyclosporine. Regimens allowing the tapering of corticosteroids have also helped reduce the rates of acute pancreas rejection. To further improve therapeutic options for patients with type 1 diabetes or end-stage renal disease, pancreatic islet transplantation and organ and islet xenotransplantation should be further explored.",
author = "Burke, {George W} and Gaetano Ciancio and Sollinger, {Hans W.}",
year = "2004",
month = "5",
day = "15",
language = "English",
volume = "77",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

TY - JOUR

T1 - Advances in pancreas transplantation

AU - Burke, George W

AU - Ciancio, Gaetano

AU - Sollinger, Hans W.

PY - 2004/5/15

Y1 - 2004/5/15

N2 - Despite early obstacles impacting the success of pancreatic transplantation, the introduction of new procedures and new immunosuppressive therapies during the past 2 decades has improved outcomes for pancreatic transplant recipients. For example, the use of bladder drainage and better human leukocyte antigen matching has helped overcome some of the early obstacles of pancreatic transplantation. In addition, the introduction of tacrolimus in 1994 and mycophenolate mofetil in 1996 has helped lower rates of acute rejection and increase graft survival, with less nephrotoxicity than treatment with cyclosporine. Regimens allowing the tapering of corticosteroids have also helped reduce the rates of acute pancreas rejection. To further improve therapeutic options for patients with type 1 diabetes or end-stage renal disease, pancreatic islet transplantation and organ and islet xenotransplantation should be further explored.

AB - Despite early obstacles impacting the success of pancreatic transplantation, the introduction of new procedures and new immunosuppressive therapies during the past 2 decades has improved outcomes for pancreatic transplant recipients. For example, the use of bladder drainage and better human leukocyte antigen matching has helped overcome some of the early obstacles of pancreatic transplantation. In addition, the introduction of tacrolimus in 1994 and mycophenolate mofetil in 1996 has helped lower rates of acute rejection and increase graft survival, with less nephrotoxicity than treatment with cyclosporine. Regimens allowing the tapering of corticosteroids have also helped reduce the rates of acute pancreas rejection. To further improve therapeutic options for patients with type 1 diabetes or end-stage renal disease, pancreatic islet transplantation and organ and islet xenotransplantation should be further explored.

UR - http://www.scopus.com/inward/record.url?scp=2442695175&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2442695175&partnerID=8YFLogxK

M3 - Article

VL - 77

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 9

ER -